Amgen Pays $2.7 Billion For Minority Stake in Chinese Biotech Firm BeiGene

American multinational biopharmaceutical company Amgen announced last week that it will pay $2.7 billion for a 20.5 percent stake in Chinese biotech firm BeiGene, a move which is seen as part of Amgen’s efforts to position itself as a developer of oncology drugs for the Chinese market...